AIM ImmunoTech (AIM) 10-Q2018 Q3 Quarterly report

Filed: 14 Nov 18, 4:43pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: arena, arm, atezolizumab, began, Bill, bladder, Boland, breast, budget, CFO, choice, cisplatin, Codification, conclusion, conversion, convey, correct, corrected, CPI, cytokine, delisted, delisting, divided, dual, Ernani, fallen, IIa, immunotherapy, InAugust, inception, intraperitoneal, IRB, Klute, lessee, lesser, linked, liver, lung, metastatic, monetary, Nebraska, negative, Nonstatutory, NSCLC, oncology, Opyrchal, overview, pembrolizumab, PI, population, portion, predominantly, promissory, rectify, repayment, reprogrammed, RPCCC, scale, secondary, settle, slated, thereunder, triple, unissued, unpaid, urothelial, variable, vi, vii, viii, VWAP, wereceived, withIliad, write

Removed: announced, Avrio, component, compound, dispute, effort, Institute, lessor, making, modified, moving, noted, Orange, Orlando, PA, Philadelphia, pursued, reached, relief, requiring, RPCI, serve, site, successor, Suite, targeted, USA, Web

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

AIM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Hemispherx Biopharma, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas K. Equels, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 14, 2018
	/s/ Thomas K. Equels
	Thomas K. Equels, Esq.
	Chief Executive Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.